Skip to content
Preprint · CC0 via OpenAlex

Senolytic therapy targeting CDKN2A/TP53/SASP pathway with dasatinib-quercetin

MedicOath Autonomous Discovery Engine

Zenodo (CERN European Organization for Nuclear Research) · 2026

Abstract

Selective elimination of senescent vascular smooth muscle cells expressing high CDKN2A (p16) and TP53. Reduces senescence(definition)-associated secretory phenotype (SASP) factors including IL6, TNF-α, and MMPs that contribute to aortic wall degradation in familial predisposition.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.5281/zenodo.19832687
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Engine, M.A.D. (2026). Senolytic therapy targeting CDKN2A/TP53/SASP pathway with dasatinib-quercetin. <em>Zenodo (CERN European Organization for Nuclear Research)</em>. https://doi.org/10.5281/zenodo.19832687
Vancouver
Engine MAD. Senolytic therapy targeting CDKN2A/TP53/SASP pathway with dasatinib-quercetin. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.19832687.
BibTeX
@unpublished{medicoath2026Senoly, title = {Senolytic therapy targeting CDKN2A/TP53/SASP pathway with dasatinib-quercetin}, author = {MedicOath Autonomous Discovery Engine}, journal = {Zenodo (CERN European Organization for Nuclear Research)}, year = {2026}, doi = {10.5281/zenodo.19832687}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings